PBA
APGE icon

Paradigm Biocapital Advisors’s Apogee Therapeutics APGE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113M Buy
1,348,243
+225,000
+20% +$16.3M 2.32% 15
2025
Q4 		$84.8M Sell
1,123,243
-398,514
-26% -$25.1M 2.16% 15
2025
Q3 		$60.5M Buy
1,521,757
+563,127
+59% +$21.5M 1.72% 18
2025
Q2 		$41.6M Sell
958,630
-3,077
-0.3% -$117K 1.78% 16
2025
Q1 		$35.9M Sell
961,707
-322,059
-25% -$12.5M 1.65% 14
2024
Q4 		$58.2M Buy
1,283,766
+581,949
+83% +$29.7M 2.02% 15
2024
Q3 		$41.2M Buy
701,817
+371,817
+113% +$17.8M 1.39% 23
2024
Q2 		$13M Hold
330,000
– – 0.5% 29
2024
Q1 		$21.9M Buy
+330,000
New +$14.4M 0.77% 27

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return